Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing… Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing of the first patient. First patient has been dosed in Safety Study 0202 of lead candidate CT001. The Safety Study 0202 is an open-label, prospective study to assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients with moderate to severe pain, in the emergency setting. Cessatech expects the study to be completed by the end of 2024. 242705 – First patient dosed in Safety Study 0202 Related articles Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗